Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
AAOAmerican Academy of Ophthalmology
ABSAustralian Bureau of Statistics
ACPAvacincaptad pegol
ADAAnti-drug antibody
AEAdverse event
AESIAdverse event of special interest
AHFSAmerican Hospital Formulary Service
AMDAge-related macular degeneration
AMPAverage manufacturer price
AREDSAge-Related Eye Disease Study
AREDS2Age-Related Eye Disease Study 2
ARMS2Age-related maculopathy susceptibility 2
ATCAnatomical Therapeutic Chemical classification
BCVABest-corrected visual acuity
BLBaseline
BLABiologics license application
BQLBelow the quantification limit
BrMBruch's membrane
BSCBest supportive care
CAMClassification of Atrophy Meetings
CBSCharles Bonnet syndrome
CFBComplement factor B
CFHComplement factor H
CFIComplement factor I
CFPColor fundus photography
CHOChinese hamster ovary
CIConfidence interval
CMSCenters for Medicare & Medicaid Services
CNVChoroidal neovascularization
CPTCurrent Procedural Terminology
cRORAComplete retinal pigment epithelium and outer retinal atrophy
CrICredible interval
CUACost-utility analysis
DHADocosahexaenoic acid
DMCData Monitoring Committee
DMEDiabetic macular edema
DSMCData and Safety Monitoring Committee
DUSCDrug Utilisation Sub-Committee
ECPEye care professional
EDEmergency department
EMEvery month
EMAEuropean Medicines Agency
EOMEvery other month
EPAEicosapentaenoic acid
EQ-5DEuroQol 5-dimension questionnaire
EREmergency room
ESCEconomics Sub-Committee
ETDRSEarly Treatment Diabetic Retinopathy Study
EUEuropean Union
EZEllipsoid zone
FabAntigen-binding fragment
FAFFundus autofluorescence
FDAU.S. Food and Drug Administration
FRIFunctional Reading Independence
GAGeographic atrophy
GBSGuillain-Barré syndrome
GPGeneral practitioner
GWASGenome-wide association study
HCPCSHealthcare Common Procedure Coding System
HCRUHealthcare resource utilization
HRHazard ratio
HTRA1High-temperature requirement A serine peptidase 1
ICERIncremental cost-effectiveness ratio
INNInternational nonproprietary name
IOPIntraocular pressure
IQRInterquartile range
iRORAIncomplete retinal pigment epithelium and outer retinal atrophy
IRISIntelligent Research in Sight registry
ITTIntention-to-treat
IVTIntravitreal
LLLetter loss
LLDLow-luminance deficit
LLVALow-luminance visual acuity
LLVDLow-luminance visual acuity deficit
LMELinear mixed effect
logMARLogarithm of the minimum angle of resolution
MAAMarketing authorisation application
MBSMedicare Benefits Schedule
MHRAMedicines and Healthcare products Regulatory Agency
MIPSMerit-based Incentive Payment System
mITTModified intention-to-treat
MMRMMixed model for repeated measures
MNVMacular neovascularization
nAMDNeovascular age-related macular degeneration
NEI VFQ-25National Eye Institute Visual Function Questionnaire, 25-item version
NHNursing home
NICENational Institute for Health and Care Excellence
NIRNear-infrared reflectance
OCTOptical coherence tomography
OCT-AOptical coherence tomography angiography
OLEOpen-label extension
OPOutpatient
OPLOuter plexiform layer
OROdds ratio
PBACPharmaceutical Benefits Advisory Committee
PBMPhotobiomodulation
PBSPharmaceutical Benefits Scheme
PDPharmacodynamics
PDCProduct Development Coordinator
PEGPolyethylene glycol
PKPharmacokinetics
POSPhotoreceptor outer segments
PPPPreferred Practice Pattern
PPYPer patient per year
PRIMEPRIority MEdicines
QALYQuality-adjusted life-year
QoLQuality of life
RCTRandomized controlled trial
REMSRisk Evaluation and Mitigation Strategy
ReSTResearch and Safety in Therapeutics
RPBSRepatriation Pharmaceutical Benefits Scheme
RPERetinal pigment epithelium
RRRelative risk
RVURelative value unit
SAESerious adverse event
SCODIScanning computerized ophthalmic diagnostic imaging
SDStandard deviation
SD-OCTSpectral-domain optical coherence tomography
SEStandard error
SFISubfoveal involvement
SS-OCTSwept-source optical coherence tomography
TEAETreatment-emergent adverse event
TTDTime to treatment discontinuation
UIUncertainty interval
VAVisual acuity
VEGFVascular endothelial growth factor
VIVisual impairment
VLVision loss
VRQoLVision-related quality of life
WHOWorld Health Organization
WTWild type
ZBIZarit Burden Interview